Article Text

Download PDFPDF
EP816 TRPV1 and PTEN expression is related to poor prognosis in epithelial ovarian cancer
  1. DB Chay1,
  2. GH Han2,
  3. H Cho2 and
  4. J-H Kim2
  1. 1Obstetrics and Gynecology, Yongin Severance Hospital, Yongin
  2. 2Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea


Introduction/Background Transient receptor potential vanilloid type-1 (TRPV-1) was previously reported to be associated with cancer. This study explored the expression of TRPV-1 and PTEN in epithelial ovarian cancer and evaluated its clinical significance.

Methodology Immunohistochemical (IHC) staining analyses of TRPV-1 and PTEN were performed using tissue microarray (TMA) constructed from 198 ovarian cancer and 47 borderline ovarian tumor samples. The clinical significance was evaluated by comparing the data with various clinicopathologic characteristics, including survival of patients with epithelial ovarian cancer.

Results TRPV-1 and PTEN expression was significantly higher in ovarian cancer compared to borderline ovarian tumor and normal human ovarian surface epithelium (HOSE) (both p<0.001). Spearman’s rank correlation analysis revealed that TRPV-1 expression shows significant correlation with PTEN expression in ovarian cancer (Spearman’s rho=0.276, p<0.001). Multivariate analysis indicated that advanced FIGO stage (III–IV) (hazard ratio=2.66 [95% CI, 1.01–6.99], p=0.046), TRPV-1 expression (hazard ratio=3.23 [95% CI, 1.06–9.80], p=0.038), PTEN expression (hazard ratio=2.98 [95% CI, 1.61–5.40], p<0.001) and combined TRPV-1/PTEN (hazard ratio=3.37 [95% CI, 1.85–6.13], p<0.001) were independent prognostic factors for overall survival.

Conclusion This study reveals the association between TRPV-1 and PTEN expression with epithelial ovarian cancer and shows that these biomarkers predicts poor prognosis. The findings of this study warrants future research evaluating its clinical usefulness.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.